For patients with GBM, the prognostic value of cIAP1, cIAP2, XIAP and ML-IAP expression remains to be determined.7, 11 Therefore, in this study we investigated ex vivo the correlation between their expression levels and patient's survival in two retrospective cohorts in order to highlight the most interesting druggable targets. The gene discussed is XIAP; the disease is glioblastoma.